Cloverleaf Bio, Inc. — SEC Form D Filing
Cloverleaf Bio, Inc. filed an SEC Form D on September 8, 2026, reporting $14.80M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- September 8, 2026
- Amount reported
- $14.80M
- Round stage
- Seed
- Industry
- Biotechnology
- Website
- https://cloverleafbio.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Current cancer therapies are inadequate, indicating a need for more effective treatments.
Solution
Cloverleaf Bio is developing a new class of RNA therapeutics aimed at improving cancer treatment.
Verdict
Investors backed this company primarily on the broad promise of applying RNA therapeutics to oncology, which offered a large potential market. This cleared because of the perceived platform nature of RNA and the high-value disease area, not because of demonstrated clinical efficacy or specific drug-target validation. Investors were implicitly betting on the team's ability to navigate complex biology and regulatory pathways in a nascent field, accepting the long development cycles inherent to drug discovery. The upside was limited by the significant technical and regulatory hurdles, which are common to novel drug modalities and reduce the probability of commercial success.
Source: SEC EDGAR Form D filing